{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T02:00:24Z","timestamp":1788055224474,"version":"build-2784847793"},"reference-count":22,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>High\u2010dose chemotherapy and autologous stem cell transplantation (ASCT) are too toxic for elderly patients with relapsed or refractory diffuse large B\u2010cell lymphoma (DLBCL). Therefore, effective and tolerable regimens for elderly patients are urgently needed. The present phase II study assessed the efficacy and safety of dose\u2010adjusted therapy with gemcitabine, dexamethasone, cisplatin, and rituximab (GDP\u2010R) in this population. ASCT\u2010ineligible elderly patients with relapsed or refractory DLBCL received dose\u2010adjusted GDP\u2010R in each 28\u2010day cycle for up to six cycles. The primary endpoint was overall response rate (ORR), and secondary endpoints were complete response (CR) rate, progression\u2010free survival (PFS), and safety. Thirty\u2010three patients were enrolled and received dose\u2010adjusted GDP\u2010R. The median age was 75 years (range: 68\u201087 years). The ORR was 82.8% (90% confidence interval [CI], 67.1\u201093.0%), with a CR rate of 58.6% (90% CI, 41.7\u201074.1%). At a median follow\u2010up of 20.9 months, the 2\u2010year PFS rate was 46.8% (90% CI, 30.7\u201061.5%) and the 2\u2010year overall survival rate was 63.2% (90% CI, 45.8\u201076.3%). The most frequently observed grade 4 adverse events were neutropenia (63.6%), thrombocytopenia (57.6%), and lymphocytopenia (39.4%). Dose\u2010adjusted GDP\u2010R is a promising salvage regimen for ASCT\u2010ineligible elderly patients with relapsed DLBCL after rituximab\u2010containing chemotherapy and warrants further investigation.<\/jats:p>","DOI":"10.1002\/jha2.111","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T19:25:30Z","timestamp":1602789930000},"page":"507-516","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Phase II study of dose\u2010adjusted gemcitabine, dexamethasone, cisplatin, and rituximab in elderly relapsed diffuse large B\u2010cell lymphoma patients"],"prefix":"10.1002","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6143-7906","authenticated-orcid":false,"given":"Satoshi","family":"Yamasaki","sequence":"first","affiliation":[{"name":"Department of Hematology and Clinical Research Institute National Hospital Organization Kyushu Medical Center  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Kada","sequence":"additional","affiliation":[{"name":"Clinical Research Center National Hospital Organization Nagoya Medical Center  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilseung","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Hematology National Hospital Organization Kyushu Cancer Center  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroatsu","family":"Iida","sequence":"additional","affiliation":[{"name":"Department of Hematology National Hospital Organization Nagoya Medical Center  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Sekiguchi","sequence":"additional","affiliation":[{"name":"Department of Hematology National Hospital Organization Disaster Medical Center  Tachikawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Hematology National Hospital Organization Kumamoto Medical Center  Kumamoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morio","family":"Sawamura","sequence":"additional","affiliation":[{"name":"Department of Hematology National Hospital Organization Shibukawa Medical Center  Shibukawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Shimomura","sequence":"additional","affiliation":[{"name":"Department of Hematology National Hospital Organization Hiroshimanishi Medical Center  Otake Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Komeno","sequence":"additional","affiliation":[{"name":"Department of Hematology National Hospital Organization Mito Medical Center  Ibaraki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yano","sequence":"additional","affiliation":[{"name":"Department of Hematology National Hospital Organization Tokyo Medical Center  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Hematologic Oncology National Hospital Organization Shikoku Cancer Center  Matsuyama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Hematology National Hospital Organization Nagasaki Medical Center  Omura Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Sunami","sequence":"additional","affiliation":[{"name":"Department of Hematology National Hospital Organization Okayama Medical Center  Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terutoshi","family":"Hishita","sequence":"additional","affiliation":[{"name":"Department of Hematology National Hospital Organization Himeji Medical Center  Himeji Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Takatsuki","sequence":"additional","affiliation":[{"name":"Department of Hematology National Hospital Organization Kokura Medical Center  Kitakyushu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Ohshima","sequence":"additional","affiliation":[{"name":"Department of Pathology School of Medicine Kurume University  Kurume Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morishige","family":"Takeshita","sequence":"additional","affiliation":[{"name":"Department of Pathology Faculty of Medicine Fukuoka University  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko M.","family":"Saito","sequence":"additional","affiliation":[{"name":"Clinical Research Center National Hospital Organization Nagoya Medical Center  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Clinical Research Institute National Hospital Organization Kyushu Medical Center  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Hematology National Hospital Organization Nagoya Medical Center  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12659"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2508"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2837"},{"issue":"7","key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/0006-2952(94)90554-1","article-title":"Schedule dependence of sensitivity to 2',2'\u2010difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours","volume":"48","author":"Haperen VWR","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12918"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.9593"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.63572"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1193852"},{"issue":"1","key":"e_1_2_10_11_1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2739\/kurumemedj.MS661001","article-title":"Rituximab\u2010mediated complement\u2010dependent cytotoxicity enhanced by gemcitabine in older patients with previously rituximab\u2010treated diffuse large b\u2010cell lymphoma: study protocol","volume":"66","author":"Yamasaki S","year":"2020","journal-title":"Kurume Med J"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-297879"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1545"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1611(199907\/08)8:4<355::AID-PON401>3.0.CO;2-I"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(98)00095-X"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.2.601"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2017.1305264"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.5203"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00172"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-012-0211-2"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.16.3025"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.111","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jha2.111","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T06:58:13Z","timestamp":1693724293000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1002\/jha2.111"],"URL":"https:\/\/doi.org\/10.1002\/jha2.111","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"assertion":[{"value":"2020-09-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}